# Eidos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eidos-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.eidostx.com
- Total disclosed funding: $26M
- Latest round: Series B (Mar 29, 2018)
- Investors on record: 8

## About

Founded in 2016 and based in California, US, Eidos Therapeutics, Inc. operates as a biotechnology company that focuses on the development of novel oral therapeutics to treat patients with transthyretin (TTR) amyloidosis (ATTR).

## Funding rounds

- Series B, Mar 29, 2018, $26M — Aisling Capital, Viking Global Investors, RA Capital Management, Cormorant Asset Management, Perceptive Advisors, BridgeBio Pharma, Inc., Janus Henderson Investors, Amzak Capital Management

## Investors

- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- BridgeBio Pharma, Inc. — Series B
- Janus Henderson Investors — Series B
- Amzak Capital Management (https://capitalatlas.ai/funds/amzak-capital-management) — Series B